Physician profile
John E Linn
NPI 1902853393
$4,291.83
in general payments reported to CMS, 2019-2025
27 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $357 · 2021: $779 · 2022: $752 · 2023: $575 · 2024: $627 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $755.93 | 2019-2024 | Idose |
| Sight Sciences, INC. | $672.71 | 2019-2025 | Omni Surgical System |
| Alcon Vision LLC | $335.27 | 2022-2025 | Clareon, Lensx, Argos |
| Johnson & Johnson Surgical Vision, INC. | $300.47 | 2019-2022 | |
| Allergan, INC. | $282.91 | 2019-2021 | |
| Ocular Therapeutix, INC. | $278.23 | 2019-2024 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $252.98 | 2019-2021 | |
| Rxsight INC | $252.87 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $214.62 | 2024-2025 | |
| Ivantis, INC | $150.21 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $125.16 | 2021 | |
| Abbvie INC. | $119.06 | 2022-2024 | |
| Optos, INC. | $89.77 | 2019 | |
| Amgen INC. | $80.00 | 2025 | Tepezza |
| Pacira Pharmaceuticals Incorporated | $54.92 | 2025 | Exparel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $52.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $38.08 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $37.57 | 2022-2025 | Xiidra, Miebo |
| Apellis Pharmaceuticals, INC. | $34.77 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $34.46 | 2021 | |
| New World Medical,INC. | $28.74 | 2022 | |
| Carl Zeiss Meditec, INC. | $27.49 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.53 | 2023 | Flarex |
| Beaver-Visitec International, INC. | $19.53 | 2020 | |
| Harrow Eye, LLC | $18.05 | 2023 | Iheezo |
| Kala Pharmaceuticals, INC. | $16.06 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Linn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.